Current trends in the use of the renin-angiotensin system blocking drugs in renovascular arterial hypertension
https://doi.org/10.38109/2075-082X-2022-1-49-54
Abstract
Renovascular hypertension (RH) is one of the most common secondary forms of arterial hypertension, in most cases caused by atherosclerotic renal artery stenosis (ARAS). The development of a course of hypertension resistant to antihypertensive therapy with an unfavorable prognosis of deterioration of kidney function and cardiovascular complications is characteristic. The review discusses the pathophysiological mechanisms of RH development in ARAS, draws attention to the important role of the renin-angiotensin system (RAS) activation, which determines the nature of the course of the disease, the high frequency of target organ damage. Modern approaches to the drug treatment of this form of hypertension, the validity and benefits of the use of drugs that block the effects of RAS in patients with RH of atherosclerotic genesis, constituting a category of high risk of cardiovascular complications, are The issues of the effectiveness of the use of these drugs in order to reduce the risk of cardiovascular complications and improve the long-term prognosis of the course of this form of hypertension are discussed.
About the Author
N. M. Chikhladze
Chazov National Medical Research Center of Cardiology
Russian Federation
Russian Federation
Novella M. Chikhladze, Dr. Sci. (Med.), National Medical Research Center of Cardiology
3rd Cherepkovskaya str., 15a, Moscow 121552
References
1. Aboyans V, Ricco J-B, Bartelink M-L, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018 Mar 1;39(9):763-816. https://doi.org/10.1093/eurheartj/ehx095, PMID: 28886620
2. Williams B, Mancia G, Spiering W, et al. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021-3104. https://doi.org/10.1093/eurheartj/ehy339, PMID: 3016551
3. Pokrovskij АV., Bogatov YuP. Vazorenal'naya gipertoniya. Gl. v kn.: Rukovodstvo po arterial'noj gipertonii. Pod red. EI Chazova, IE Chazovoj. M.: MediaMedika. 2005;95-117 (in Russian).
4. Shilov EM, Batyushkin MM. Renovaskulyarnaya arterial'naya gipertenziya i ishemicheskaya bolezn' pochek. V kn.: Nefrologiya. Klinicheskie rekomendatsii. Pod red. EM.Shilova, АV Smirnova, NL Kozlovskoj. M.: GEOTАR-Media. 2016;449-460 (in Russian).
5. Textor SC. Renal Arterial Disease and Hypertension. Med Clin North Am. 2017 Jan;101(1):65-79. https:// doi.org/10.1016/j.mcna.2016.08.010, PMID: 27884236
6. Herrmann SM, Textor SC. Current Concepts in the Treatment of Renovascular Hypertension. Am J Hypertens. 2018 Jan 12;31(2):139-149. https://doi.org/10.1093/ajh/hpx154, PMID: 28985335
7. Dobrek L. An Outline of Renal Artery Stenosis Pathophysiology-A Narrative Review. Life (Basel). 2021 Mar 7;11(3):208. https://doi.org/10.3390/life11030208, PMID: 33799957
8. Coen G, Calabria S, Lai S, et al. Atherosclerotic ischemic renal disease. Diagnosis and prevalence in an hypertensive and/or uremic elderly population. BMC Nephrol. 2003 Feb 6;4:2. https://doi.org/10.1186/1471-2369-4-2, PMID: 12622875
9. Khatami MR. Ischemic nephropathy: more than a simple renal artery narrowing. Iran J Kidney Dis. 2013 Mar;7(2):82-100. PMID: 23485531.
10. Conlon PJ, Little MA, Pieper K, Mark DB. Severity of renal vascular disease predicts mortality in patients undergoing coronary angiography. Kidney Int. 2001 Oct;60(4):1490-7. https://doi.org/10.1046/j.1523-1755.2001.00953.x, PMID: 11576364
11. Mukhin NА, Fomin VV. Аteroskleroticheskij stenoz pochechnykh arterij. V kn.: Rukovodstvo po aterosklerozu i ishemicheskoj bolezni serdtsa. Pod red. EI CHazova., VV Kukharchuka, SА Bojtsova. Media Medica, 2007; 248-273 (in Russian).
12. Benjamin MM, Fazel P, Filardo G, et al. Prevalence of and risk factors of renal artery stenosis in patients with resistant hypertension. Am J Cardiol. 2014 Feb 15;113(4):687-90. https://doi.org/10.1016/j. amjcard.2013.10.046, PMID: 24342757
13. Ritchie J, Green D, Chrysochou C, Chalmers N, et al. High-risk clinical presentations in atherosclerotic renovascular disease: prognosis and response to renal artery revascularization. Am J Kidney Dis. 2014 Feb;63(2):186-97. https://doi.org/10.1053/j.ajkd.2013.07.020, PMID: 24074824
14. Losito A, Fagugli RM, Zampi I, et al. Comparison of target organ damage in renovascular and essential hypertension. Am J Hypertens. 1996 Nov;9(11):1062-7. https://doi.org/10.1016/0895-7061(96)00199-9, PMID: 8931830
15. Chrysochou C, Foley RN, Young JF, et al. Dispelling the myth: the use of renin-angiotensin blockade in atheromatous renovascular disease. Nephrol Dial Transplant. 2012 Apr;27(4):1403-9. https://doi.org/10.1093/ndt/gfr496, PMID: 21993376
16. Sofroniadou S., Kassimatis T., Srirajaskanthan R. et al. Long-term safety and efficacy of renin– angiotensin blockade in atherosclerotic renal artery stenosis. Int Urol Nephrol. 2012 Oct;44(5):1451-9. https://doi.org/10.1007/s11255-011-0091-y, PMID: 22127407
17. de Mast Q, Beutler JJ. The prevalence of atherosclerotic renal artery stenosis in risk groups: a systematic literature review. J Hypertens. 2009 Jul;27(7):1333-40. https://doi.org/10.1097/HJH.0b013e328329bbf4, PMID: 19365285.
18. Kalra PA, Guo H, Kausz AT, et al. Atherosclerotic renovascular disease in United States patients aged 67 years or older: risk factors, revascularization, and prognosis. Kidney Int. 2005 Jul;68(1):293-301. https://doi.org/10.1111/j.1523-1755.2005.00406.x, PMID: 15954920.
19. Bavishi C, de Leeuw PW, MD, Messerli FH. Atherosclerotic Renal Artery Stenosis and Hypertension: Pragmatism, Pitfalls, and Perspective. Am J Med. 2016 Jun;129(6):635.e5-635.e14. https://doi.org/10.1016/j.amjmed.2015.10.010, PMID: 26522797
20. Van der Niepen P, Rossignol P, Lengele J-P, et al. Renal Artery Stenosis in Patients with Resistant Hypertension: Stent It or Not? Curr Hypertens Rep. 2017;19(1):5. https://doi.org/10.1007/s11906-017-0703-8, PMID: 28150134
21. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013 Jul;31(7):1281-1357. https://doi.org/10.1097/01.hjh.0000431740.32696.cc, PMID: 23817082
22. Balafa O, Kalaitzidis R, Siamopoulos KC. Optimal medical management in patients with renovascular hypertension. Am J Cardiovasc Drugs. 2013 Apr;13(2):71-8. https://doi.org/10.1007/s40256-013-0011-x, PMID: 23494905
23. Cooper CJ, Murphy TP, Cutlip DE, et al. CORAL Investigators. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med. 2014 Jan 2;370(1):13-22. https://doi.org/10.1056/ NEJMoa1310753, PMID: 24245566
24. Vassallo D, Kalra PA. Progress in the treatment of atherosclerotic renovascular disease: the conceptual journey and the unanswered questions. Nephrol Dial Transplant. 2016 Oct;31(10):1595-605. https://doi.org/10.1093/ndt/gfv278, PMID: 26187997
25. Herrmann SM, Textor SC Renovascular hypertension. Endocrinol. Metabol. Clin. N. Am. 2019;48:765-778. https://doi.org/10.1016/j.ecl.2019.08.007, PMID: 31655775
26. Senitko M, Fenves AZ. An Update on Renovascular Hypertension. Curr. Cardiol. Rep. 2005;7:405–411. https://doi.org/10.1007/s11886-005-0057-8, PMID: 16256008
27. Hricik DE, Browning PJ, Kopelman R, et al. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney. N Engl J Med. 1983 Feb 17;308(7):373-6. https://doi.org/10.1056/NEJM198302173080706, PMID: 6337327.
28. Hackam DG, Duong-Hua ML, Mamdani M, et al. Angiotensin inhibition in renovascular disease: A population-based cohort study. Am Heart J. 2008 Sep;156(3):549-55. https://doi.org/10.1016/j.ahj.2008.05.013, PMID: 18760140
29. Garovic VD, Textor SC. Renovascular hypertension and ischemic nephropathy. Circulation. 2005 Aug 30;112(9):1362-74. https://doi.org/10.1161/CIRCULATIONAHA.104.492348, PMID: 16129817
30. Tendera M., Aboyans V, Bartelink ML et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases. Eur Heart J. 2011 Nov;32(22):2851-906. https://doi.org/10.1093/eurheartj/ehr211, PMID: 21873417
31. Dahlöf B, Devereux RB, Kjeldsen SE, et al. LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): A randomised trial against atenolol. Lancet. 2002 Mar 23;359(9311):995-1003. https://doi.org/10.1016/S0140-6736(02)08089-3, PMID: 11937178
32. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA. 1996 May 15;275(19):1507-13. PMID: 8622227.
33. Kobori H, Nangaku ML, Navar G, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007 Sep;59(3):251-87. https:// doi.org/10.1124/pr.59.3.3, PMID: 17878513
34. Evans KL, Tuttle KR, Folt DA, et al. Use of renin-angiotensin inhibitors in people with renal artery stenosis. Clin J Am Soc Nephrol. 2014 Jul;9(7):1199-206. https://doi.org/10.2215/CJN.11611113, PMID: 24903387
35. Zhu XY, Chade AR, Rodriguez Porcel M, et al. Cortical microvascular remodeling in the stenotic kidney: role of increased oxidative stress. Arterioscler Thromb Vasc Biol. 2004 Oct;24(10):1854-1859. https://doi.org/10.1161/01.atv.0000142443.52606.81, PMID: 15308558
36. Lerman LO, Textor SC, Grande JP. Mechanisms of tissue injury in renal artery stenosis: ischemia and beyond. Prog Cardiovasc Dis. 2009 Nov-Dec;52(3):196-203. https://doi.org/10.1016/j.pcad.2009.09.002, PMID: 19917330
37. Zhang X, Eirin A, Li ZL, et al. Angiotensin receptor blockade has protective effects on the poststenotic porcine kidney. Kidney Int. 2013 Oct;84(4):767-75. https://doi.org/10.1038/ki.2013.144, PMID: 23615504
38. Losito A, Errico R, Santirosi P, et al. Long-term follow-up of atherosclerotic renovascular disease. Beneficial effect of ACE inhibition. Nephrol Dial Transplant. 2005 Aug; 20(8):1604-9. https://doi.org/10.1093/ndt/gfh865, PMID: 15870215
39. Brugts JJ, Boersma E, Chonchol M, et al. EUROPA Investigators. The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial. J Am Coll Cardiol. 2007 Nov 27;50(22):2148-55. https://doi.org/10.1016/j.jacc.2007.08.029, PMID: 18036453
40. Mann JF, Gerstein HC, Pogue J, et al. HOPE Investigators: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med. 2001 Apr 17;134(8):629-636. https://doi.org/10.7326/0003-4819-134-8-200104170-00007, PMID: 11304102
41. SOLVD Investigators, Yusuf S, Pitt B, Davis CE, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991 Aug 1;325(5):293-302. https://doi.org/10.1056/NEJM199108013250501, PMID: 2057034
42. Khosla S, Ahmed A, Siddiqui M, et al. Safety of angiotensin-converting enzyme inhibitors in patients with bilateral renal artery stenosis following successful renal artery stent revascularization. Am J Ther. 2006 Jul-Aug;13(4):306-8. https://doi.org/10.1097/00045391-200607000-00005, PMID: 16858164
43. Kutyrina IM, Shvetsov MYu, Fomin VV, et al. Аrterial'naya gipertoniya pri khronicheskoj bolezni pochek. V kn.: Nefrologiya. Klinicheskie rekomendatsii. Pod red. EM Shilova, АV Smirnova, NL Kozlovskoj. M.: GEOTАR-Media, 2016;389-448 (in Russian)
44.
Review
For citations:
Chikhladze N.M. Current trends in the use of the renin-angiotensin system blocking drugs in renovascular arterial hypertension. Systemic Hypertension. 2022;19(1):49-54. (In Russ.) https://doi.org/10.38109/2075-082X-2022-1-49-54
Views:
356
Email this article 